Christian Heidbreder compensation by year
Indivior Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $603,405 | $630,558 | $652,628 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $1,556,976 | $1,663,461 | $2,689,676 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $615,473 | $155,117 | $783,154 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $76,274 | $57,861 | $57,090 |
| Total | $2,852,128 | $2,506,997 | $4,182,548 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Indivior Pharmaceuticals, Inc. DEF 14A filed March 27, 2026, accession 0001104659-26-035480, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Indivior Pharmaceuticals, Inc. filed document, accession 0001104659-26-035480. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 192,004 | $6,889,104 | — |
| PSU | 114,092 | $4,093,621 | — |
| PSU | 101,544 | $3,643,399 | — |
| RSU | 82,287 | $2,952,458 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Indivior Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Indivior Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $652,628 | — | $21,777 | $1,065,981 |
| Resignation for good reason, no change in control | $652,628 | — | $21,777 | $1,065,981 |
| Change in control and involuntary termination | $1,305,256 | — | $43,555 | $2,131,963 |
| Change in control and resignation for good reason | $1,305,256 | — | $43,555 | $2,131,963 |
Per the Potential Payments Upon Termination or Change in Control table in Indivior Pharmaceuticals, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Indivior Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joe Ciaffoni | Chief Executive Officer | $18,501,214 |
| Pat Barry | Chief Commercial Officer | $4,905,744 |
| Christian Heidbreder · this page | Chief Scientific Officer | $4,182,548 |
| Richard Simkin | Former Chief Commercial Officer | $4,017,316 |
| Ryan Preblick | Chief Financial Officer | $3,592,393 |
| Jeff Burris | Chief Legal Officer | $3,521,215 |
| Mark Crossley | Former Chief Executive Officer | $3,185,591 |
The full Indivior Pharmaceuticals compensation record
free company briefThis page is one person within Indivior Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Indivior Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Indivior Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Indivior Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order INDV
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.